Stay updated with breaking news from Nicolas Wein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Alcyone Therapeutics Inc. ("Alcyone"), a biotechnology company pioneering next-generation precision gene-based therapies for complex...
/PRNewswire/ -- Alcyone Therapeutics Inc. ("Alcyone"), a biotechnology company pioneering next-generation precision gene-based therapies for complex...
/PRNewswire/ -- Alcyone Therapeutics Inc. ("Alcyone"), a biotechnology company pioneering next-generation precision gene-based therapies for complex...
Share this article Share this article LOWELL, Mass., June 9, 2021 /PRNewswire/ -- Alcyone Therapeutics ("Alcyone"), a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions, today announced its launch and $23 million in funding from funds affiliated with RTW Investments, LP ("RTW"). Piratip Pratumsuwan, Managing Director at RTW, will join Alcyone's Board of Directors. Alcyone's optioned pipeline currently includes 12 adeno-associated virus (AAV) gene therapy pro...